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Abstract: Background: Eel calcitonin (elcatonin) injection is widely used for elderly patients suffering from somatic pain 
in Japan. However, there have been few reports on the analgesic effects of elcatonin injection. The purpose of this study 
was to examine the analgesic effects of elcatonin injection in postmenopausal women with lower back pain. 
Methods: This study was designed as a double-blind, randomized, placebo-controlled study. Thirty-six women aged 50 
years with acute lower back pain participated in this study. They were randomly divided into two treatment groups 
according to whether they received a placebo or a weekly trigger point injection of elcatonin (20 units). They were 
observed for 5 weeks and the extent of pain at motion and at rest according to the visual analog scale (VAS) was 
evaluated. The mean VAS scores for the elcatonin group were then compared with those of the placebo group. 
Results: There were no statistically significant differences in the mean VAS scores for pain at rest between the two groups 
during the 5-week treatment course. However, the mean VAS scores for motion pain in the elcatonin group were 
significantly lower than those in the placebo group at the third, fifth and sixth weeks. 
Conclusions: Elcatonin injection (20 units) significantly relieved motion pain in the lower back in postmenopausal women 
after three weeks of treatment. This analgesic effect continued for the subsequent 3 weeks. 
Keywords: Postmenopause, back pain, anti-nociceptive. 
INTRODUCTION 
  The frequency of hospital visits by elderly patients is 
apparently increasing. Among these patients, lower back 
pain is a relatively common complaint. 
  Calcitonin is a polypeptide hormone secreted from the 
parafollicular C cells of the thyroid gland [1, 2]. This 
hormone is involved in the regulation of calcium 
homeostasis in blood and its metabolism in bone [3]. 
Repeated intramuscular or intravenous injection of calcitonin 
alleviates pain related to osteoporosis [4], and it is widely 
used in clinical practice as a treatment for elderly patients. 
  A previous meta-analysis confirmed the analgesic effects 
of salmon calcitonin (100 to 200 IU), which is administered 
either intranasally or intramuscularly, on lower back pain 
associated with osteoporotic vertebral compression fracture 
[5]. However, such high doses of calcitonin are not 
sanctioned in Japan. Instead, elcatonin (20 units), which is a 
calcitonin intramuscular injection, has been widely used. 
However, there are few reports on the analgesic effects of 
elcatonin injection [6]. 
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  Postomenopausal women visit our institution for lower 
back pain and are regularly treated with elcatonin injection 
therapy. However, as the evidence for this therapy is 
insufficient, we decided to investigate its efficacy in clinical 
practice. We hypothesized that elcatonin injection treatment 
is an effective method for the relief of lower back pain. We 
therefore examined the analgesic effects of elcatonin (20 
units) treatment in postmenopausal women in regard to 
resting pain and motion pain in the lower back in a 2-year, 
double-blind, randomized, placebo-controlled study. 
MATERIALS AND METHODOLOGY 
Subjects 
 Women  aged   50 years with acute lower back pain and 
who visited to Suwa Red Cross Hospital from August 2001 
to March 2003 were enrolled in this study. The inclusion and 
exclusion criteria are listed (Table 1). Patients who were not 
able to sit up because of severe back pain, and suspected to 
have a fresh vertebral fracture, were excluded from the 
study. Whether they had any vertebral fracture or not was 
determined using standard anteroposterior and lateral 
radiographs of the spine in the standing position. The study 
was approved by the Ethics Committee of Suwa Red Cross 
Hospital. We explained the contents of the study to the 
patients who satisfied the inclusion criteria, and those 
providing informed consent were enrolled as study subjects. Elcatonin Treatment for Back Pain  The Open Orthopaedics Journal, 2010, Volume 4    133 
Randomization and Clinical Intervention 
  When the participants first visited our hospital, we used 
the envelope method to randomly divide them into the 
elcatonin group and the placebo group. The elcatonin group 
was given a trigger point injection of a mixture of elcatonin 
(20 units) and 1% lidocaine hydrochloride (8 ml). The 
placebo group was given trigger point injection of a mixture 
of the placebo (1% lidocaine hydrochloride [1 ml]) and 1% 
lidocaine hydrochloride (8 ml). The patients and operators 
were blinded in regard to the medicines injected. The 
injections were repeated once weekly until pain relief. We 
entrusted the timing of injection termination to each 
participant. Participants had regularly taken nonsteroidal 
anti-inflammatory drugs (etodolac, 100 mg) three times per 
day until sufficient relief of their pain. They also regularly 
took active vitamin D3 and calcium everyday throughout the 
study period. 
Measurement Variables 
  Participants' lower back pain was classified as “resting 
pain” or “motion pain”. Resting pain meant the pain caused 
by keeping the recumbent, sitting or standing position. 
Motion pain meant the pain caused by changing the posture, 
for example, recumbent to sitting or sitting to standing 
position. However, it may be difficult to distinguish these 
pains accurately. Therefore, we asked patients to determine 
which type of pain they had. Participants were ordered to 
report their resting pain and motion pain weekly using the 
visual analog scale (VAS) as well as the amount of NSAIDs 
taken during the previous week. We evaluated each 
participant from the week of her first visit until the sixth 
week (for 5 weeks). We also evaluated the total injection 
volume and the amount of NSAIDs used by each participant. 
We measured the bone mineral density (BMD) at the 
posteroanterior spine (L2-4) and biochemical bone markers 
(serum levels of bone alkaline phosphatase [BAP] and urine 
levels of cross-linked N-telopeptides of type I collagen 
[NTx]) as baseline data for the participants at the time of 
their first visit to our hospital. BMD was measured with a 
dual-energy X-Ray absorptiometry (DXA) fan-beam bone 
densitometer (Hologic QDR 2000; Hologic Waltham, MA). 
Data Analysis 
  We excluded inappropriate cases prior to performing the 
analysis. We assessed the differences in the mean VAS 
scores between the elcatonin group and the placebo group in 
regard to both resting pain and motion pain. We performed 
an analysis of variance with repeated measures to determine 
the differences between the two groups and over time. If a 
significant difference was detected between the elcatonin 
group and the placebo group by the analysis, we performed 
Welch’s t test between the two groups regarding the mean 
VAS scores for each week. We also assessed the differences 
between the means in baseline data (age, BMD, serum BAP, 
and urinary NTx) in each group by Welch’s t test. We 
considered p < 0.05 to indicate significance in all analyses. 
The statistical analysis was performed using SPSS for 
Windows 17.0 software program (SPSS, Chicago, IL, USA). 
RESULTS 
 Fig.  (1) shows the flow diagram throughout the trial. 
Thirty-six patients participated in the trial, and four of these 
were excluded before opening the study key. Seventeen 
patients were in the elcatonin group and 15 patients were in 
the placebo group. 
  Of the excluded participants, three were assigned to the 
elcatonin group and one was assigned to the placebo group. 
In the elcatonin group, two participants did not attend a 
follow-up on the second week, and one participant was not 
able to continue with the intervention beyond the third week. 
One of the participants missing the follow-up canceled 
further visits to our department because of adequate pain 
relief at 2 days after the first injection. The other patient was 
admitted to the hospital after 1 week with an eye disease that 
was unrelated to the study intervention, although she stated 
that she experienced sufficient pain relief to go on a trip after 
the first injection. The participant who was unable to 
continue intervention suffered pain and muscular weakness 
in her left leg at 2 weeks after the first injection and was 
admitted to our department. She has since received 
conservative treatment under a diagnosis of lumbar spinal 
canal stenosis and has since achieved sufficient pain relief. 
In the placebo group, only one participant failed to attend 
follow-up on the fourth week, having decided to forego 
further participation in the study. However, this patient also 
reported a gradual decrease in pain. 
  There were no significant differences in the mean age, 
BMD or biochemical bone markers between the two groups 
at the first visit (Table 2). The number of clinical 
interventions did not significantly differ between the 
elcatonin and placebo groups. The mean number of 
injections was 2.5 ± 0.2 (mean ± standard error) in the 
elcatonin group, and 3.1 ± 0.5 in the placebo group, although 
this difference was not significant (p = 0.24, 95% confidence 
interval [95% CI] -1.7, -0.4). In addition, there were no 
significant differences in the mean amount of NSAIDs used 
Table 1.  Inclusion and Exclusion Criteria for the Trial 
 
Inclusion Criteria  Exclusion Criteria 
Postmenopausal woman  Premenopausal woman 
Pain, primarily in lower back   Pain at several sites, e.g., buttock, thigh 
Able to regularly visit hospital  Bedridden due to severe pain 
Acute moderate back pain including unrecognizable vertebral fractures by X-Ray  Obvious fresh vertebral fracture, as diagnosed by X-Ray 
  Prior use of elcatonin 
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between the two groups (99.0 ± 3.9 tablets in the elcatonin 
group, 84.0 ± 8.2 tablets in the placebo group; p = 0.11, 95% 
CI 3.9, 33.9). 
  The patterns of pain at rest were very similar in the 
elcatonin and placebo groups (Fig. 2). The mean VAS scores 
were roughly 3.0 at the time of the first visit in each group 
(3.00 ± 2.60 in the elcatonin group, 2.83 ± 2.65 in the 
placebo group), and these values decreased over time, 
reaching nearly 0 in the fifth week (0.20 ± 0.35 in the 
elcatonin group, 0.34 ± 0.59 in the placebo group). There 
was a significant effect of the passage of time after the first 
visit, but there were no significant effect in regard to the type 
of injected drugs and no significant interaction between the 
drugs and the course of time (Table 3 ). In contrast, the 
course and extent of motion pain were not similar between 
the two groups. The mean VAS scores differed between the 
two groups, although the values in both groups decreased 
over time (Fig. 2). There were significant effects in regard to 
the time and the type of drug, but there was no significant 
interaction between these two factors (Table 3 ). Although 
the mean VAS scores of the two groups were similar at the 
time of first visit (6.91 ± 1.93 in the elcatonin group, 7.04 ± 
2.44 in the placebo group), the mean VAS score of the 
elcatonin group decreased to a greater degree than that of the 
placebo group during the evaluation period. There was a 
statistically significant difference in the mean VAS scores 
between the two groups at the third (p = 0.047), fifth (p = 
0.047) and sixth weeks (p = 0.023). No adverse events were 
observed during the course of the trial. 
DISCUSSION 
  We observed that the injection of elcatonin (20 units) was 
more effective at relieving lower back motion pain than a 
placebo in postmenopausal women; however, elcatonin was 
not significantly more effective at relieving pain at rest as 
compared with a placebo. Postmenopausal women tend to 
have lower back pain, particularly during motion, which 
often disturbs their activities of daily living. An injection of 
elcatonin (20 units) is useful for the relief of this type of 
pain. 
  Menopause is known to be a cause of osteoporosis in 
humans. Postmenopausal women often suffer from pain in 
their daily lives. One of the most important changes 
following menopause is the depletion of estrogen, which 
regulates gene expression. The depletion of this hormone 
influences the amount of gene products, including receptors 
and peptides (e.g. calcitonin) required for the modulation of 
nociceptive transmission. Accordingly, the depletion of 
 
Fig. (1). Flow diagram showing the flow of participants through the trial. 
Table 2.  Baseline Data for the Elcatonin and Placebo Groups 
 
Difference 
  Elcatonin Group  Placebo Group 
p Value  95% CI 
Number of participants  17 15     
Age (years)  71.5 ± 2.2  72.7 ± 2.1  0.688  -7.4, 5.0 
BMD at lumbar spine (g/cm
2)  0.751 ± 0.029  0.660 ± 0.048  0.119  -0.025, 0.207 
Serum BAP (U/L)  30.8 ± 3.1  33.8 ± 3.0  0.497  -11.8, 5.9 
Urinary NTx (nmol BCE/mmol Cr)  71.6 ± 11.4  59.5 ± 7.5  0.381  -15.8, 40.1  
Values are listed as the mean ± standard error. 95% CI; 95% confidence interval. 
Assessed for eligibility (n=47)
Excluded (n=11)
    Refused to participate (n=11)
Lost to follow up (n=2)
Discontinued intervention (n=1)
Analysed (n=17)
 
Excluded from analysis (n=0)
Placebo (n=16)
    Received allocated intervention (n=16)
Lost to follow up (n=1)
Discontinued intervention (n=0)
Analysed (n=15)
 
Excluded from analysis (n=0)
Randomised (n=36)
Elcatonin (n=20)
    Received allocated intervention (n=20)Elcatonin Treatment for Back Pain  The Open Orthopaedics Journal, 2010, Volume 4    135 
estrogen can cause hyperalgesia [7]. This change in the level 
of genetic expression is one of the triggers for the pain 
accompanying postmenopausal osteoporosis. 
  Local ischemia in the paraspinal muscles is associated 
with changes in spinal alignment and participates in lower 
back pain in postomenopausal women. Degenerative or 
traumatic changes in spinal alignment tend to cause fatigue 
pain while maintaining an unnatural posture. Such changes 
in paraspinal muscle alignment may cause local tissue 
ischemia, which consequently leads to localized pain [8]. 
The mechanism of such ischemic pain is attributed to the fact 
that the lack of oxygen causes an increase in lactic acid, 
leading to acidosis. Algesic substances such as kallikrein and 
bradykinin are subsequently generated, thereby causing pain. 
  As mentioned above, it is thought that postmenopausal 
women are more vulnerable to lower back pain. Some 
authors have reported that calcitonin is effective for relieving 
lower back pain in such patients and have suggested several 
mechanisms in regard to how calcitonin acts as an anti-
nociceptive substance. The mechanisms of anti-nociception 
by calcitonin can be generally categorized as either direct 
central action or indirect peripheral action. 
  Calcitonin can act as an anti-nociceptive substance on the 
central nociceptive system. It is known that the central 
monoaminergic systems, such as the serotonergic and 
noradrenergic systems, contribute to the modulation of 
nociceptive transmission. Several reports have implicated the 
involvement of the serotonergic [9-11] and 
catecholaminergic systems [12] in calcitonin-induced anti-
nociception. Moreover, the contribution of the serotonergic 
system to the anti-nociceptive effects of peripherally injected 
calcitonin has been suggested. Several authors have reported 
that elcatonin injection increases the level of spinal 
serotonergic receptor expression in ovariectomized rats and 
is also involved in antinociception [13, 14]. 
  Furthermore, calcitonin may clinically contribute to pain 
relief through the improvement of blood flow. Nagai et al. 
reported that calcitonin improves blood flow in the legs and 
raises skin temperature [15, 16]. Accordingly, calcitonin may 
increase blood flow systemically as well as in the legs. 
However, Brain et al. reported that the vasodilatory effects 
of calcitonin are weak [17], and therefore the mechanisms of 
increased blood flow by calcitonin remain unclear. If the 
injection of calcitonin leads to increased blood flow in the 
paraspinal muscles, it may be possible to flush out algesic 
Table 3.  The Weekly Mean VAS Scores from the Start of Treatment (First Week) to Five Weeks Later (Sixth Week) in the 
Elcatonin and Placebo Groups 
 
Week p  Value 
  Group 
0  1 2 3 4  5  Time  Group 
Time  
  
Group 
Elcatonin   3.00 ± 2.60  2.56 ± 2.28  1.16 ± 1.14  0.73 ± 1.15  0.39 ± 0.68  0.20 ± 0.35  <0.001   0.969   0.992  
Placebo   2.83 ± 2.65  2.81 ± 2.87  1.03 ± 1.31  0.70 ± 0.93  0.43 ± 0.55  0.34 ± 0.59       
Pain  
at  
rest  Difference  
(95%CI)  
0.17  
(-1.73, 2.07) 
-0.24  
(-2.14, 1.65) 
0.13  
(-0.77, 1.02) 
0.03  
(-0.72, 0.79) 
-0.03  
(-0.48, 0.41) 
-0.14  
(-0.50, 0.22) 
   
Elcatonin   6.91 ± 1.93  4.62 ± 1.89  3.06 ± 2.05  1.83 ± 1.84  0.77 ± 0.83  0.38 ± 0.49  <0.001   0.037   0.542  
Placebo   7.04 ± 2.44  5.47 ± 3.28  4.87 ± 2.76  3.03 ± 3.09  2.05 ± 2.18  1.77 ± 2.09       
Pain  
at  
motion 
Difference  
(95%CI)  
-0.13  
(-1.74, 1.48) 
-0.86  
(-2.86, 1.14) 
-1.81  
(-3.59, -0.02) 
-1.20  
(-3.09, 0.69) 
-1.28  
(-2.53, -0.02) 
-1.40  
(-2.57, -0.22) 
   
Values are listed as the mean ± standard deviation. 95% CI; 95% confidence interval. 
 
Fig. (2). The extent of pain after the first injection of elcatonin or placebo. The means of the visual analogue scale value for each group are 
shown. Error bars indicate the standard error. *p < 0.05. 
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substances and to relieve ischemic or fatigue pain. 
  We formed a hypothesis about the analgesic effect of 
elcatonin injection in postmenopausal women. Acute lower 
back pain that is so severe as to prevent movement is 
typically due to vertebral compression fractures in 
osteoporotic patients [18]. These fractures are recognized 
and diagnosed in only one third of the patients who suffer 
from them [19]. While this condition is not commonly 
associated with back pain, some vertebral fractures can cause 
various degrees of back pain in elderly patients. Therefore, 
unrecognized vertebral fractures may be involved in even 
moderate back pain in elderly women [20]. Patients who had 
back pain due to such unrecognized vertebral fractures were 
allowed to participate in this trial. A limitation of our study 
is the lack of identification of such fractures in the 
participants of this trial because of the non-performance of 
MRI or scintigraphy. Chronic lower back pain, which 
primarily occurs at motion, is thought to be caused by 
articular facets, ligaments, muscle, and fascia connected with 
vertebral deformities after fractures in postmenopausal 
osteoporotic women. Pain in the muscle and fascia is thought 
to be fatigue pain or ischemic pain. Elcatonin may relieve 
such pain by increasing blood flow in the early phase of 
treatment. 
  Furthermore, elcatonin may cause pain relief in 
postmenopausal women by controlling hyperalgesia caused 
by calcitonin insufficiency due to estrogen insufficiency. 
Therefore, the anti-nociceptive effects of elcatonin may 
persist for some time after stopping treatment. 
  We demonstrated that the injection of elcatonin (20 units) 
relieves motion pain in the lower back in postmenopausal 
women. This injection is often performed in postmenopausal 
osteoporotic women with lower back pain. We propose that 
elcatonin should be administered to patients who complain 
of motion pain in their lower back. If this calcitonin drug is 
appropriately used in such patients, it will effectively relieve 
pain. 
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